- October 14, 2018
- Posted by: PharmaScroll
In a breakthrough human study, published in Eureka Alert, anti-oxidant, glutathione (GSH), which protects the brain from stress, has been found to be significantly depleted in Alzheimer’s patients compared to normal subjects. As GSH is a very important anti-oxidant that protects the brain from free radicals, the findings give us another measure to use when diagnosing potential for the advancement of Alzheimer’s disease or recognizing those that are in the throes of Alzheimer’s advancement.
By implementing non-invasive imaging techniques, Dr. Mandal and his team of researchers found that GSH has two conformations (closed and extended forms) in the brain. It was discovered that when GSH is depleted in the hippocampus regions of an elderly person the healthy brain suffers mild cognitive impairment (MCI), which is known to be present in the earlier stages of AD. It is now correlated that closed form of GSH is depleted in AD patients. At present no report is available to indicate to what extent the lower levels of extended form of GSH in those suffering from AD can be measured but it opens the possibility for further clinical observation using GSH as supplement to combat the advancement of AD.
“If routine non-invasive tests for lower levels of GSH in the hippocampus regions are performed, we might be able to mitigate the advancement of Alzheimer’s disease by providing GSH supplements- A observational study is planned” Dr. Mandal said.
The multi-continent research team lead by Dr. Mandal, led this breakthrough research and this research has a huge potential for therapeutic development for AD.
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Alzheimer’s disease indication, visit https://pharmascroll.com/news-category/alzheimers/
News Source: https://www.eurekalert.org/pub_releases/2018-10/ip-ans101218.php